anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Astragaloside IV(ASⅣ), the main component of Radix Astragali, has been used to treat cerebral ischemia reperfusion injury (CIRI). However, the molecular mechanism of ASIV in CIRI needs to be further elucidated. Long non-coding RNA (lncRNA) is considered to be an important kind of regulatory molecule in CIRI. In this work, the biological effect and molecular mechanism of ASIV in CIRI through lncRNA were analyzed by using rat middle cerebral artery occlusion and reperfusion (MCAO/R) model and primary rat microglia (RM) cells oxygen and glucose deprivation/reoxygenation (OGD/R) model. The neurological deficit score was evaluated, the volume of cerebral infarction was calculated, and pyroptosis related molecules were detected by qPCR and western blot. Then, high-throughput sequencing was performed in sham and MCAO/R groups. The competitive endogenous RNA (ceRNA) networks associated with pyroptosis were constructed by functional enrichment analysis. CCK-8 detection of cell survival rate, qPCR and western blot were used to determine the specific molecular mechanism of ASⅣ through ceRNA in vitro. Results showed thatASⅣ could decrease the neurological deficit score, reduce the volume of cerebral infarction, inhibit inflammatory reaction and pyroptosis in MCAO/R model rats. Next, the ceRNA network was established, including the LOC102555978/miR-3584-5p/NLRP3 regulatory network. In vitro experiments showed that LOC102555978 promotes NLRP3 mediated pyroptosis of RM cells through sponge adsorption of miR-3584-5p, which may provide a potential therapeutic target for post-CIRI inflammation regulation. ASⅣ could inhibit pyroptosis of RM cells by down-regulating LOC102555978. LOC102555978/miR-3584-5p/NLRP3 may be the molecular mechanism of ASⅣ's CIRI protective effect.
Aneurysms and dissection involving the ascending aorta and aortic arch have historically been treated with open surgical techniques, requiring cardiopulmonary bypass and deep hypothermic circulatory arrest (DHCA). Despite increasing experience and refinement of these procedures, there remains a substantial rate of morality and morbidity. Total endovascular aortic arch and ascending aorta repair is one of the ultimate solutions of these diseases. However, this approach requires extensive technique and new device development. The goal of total endoluminal stent grafting is to re-construct the ascending aorta and aortic arch to cover the primary entry tear of the dissection and to remodel the aorta.Recently, branch and fenestrated stent-grafts has been developed to treat complex ascending and aortic arch disease, which was previously considered to be contraindicated for endovascular repair. This study aims to investigate the short to mid term efficacy and safety of a newly-developed branched stent graft in patients who had complex aortic lesions, such as ascending aortic/arch aneurysm, pseudo-aneurysm, Stanford Type A dissection, retrograde Stanford Type B dissection, dissection with primary tear located in the aortic arch, et al.

Primary outcome measure is all-cause mortality. Secondary outcome variables include conversion to stent and/or surgery, induced thrombosis of the false lumen, cardiovascular morbidity, aortic expansion (\>5 mm/y of maximum diameter including true and false lumina), quality of life, and length of intensive care unit and hospital stay. The study designs to enroll 50 patients to be monitored for 24 months.
Use of a lymphotoxin beta receptor activating agent, preferably a lymphotoxin beta-receptor antibody (anti LT-beta -R-AB), for preparing a pharmaceutical composition for the prevention and/or treatment of obesity, obesity associated diabetes (type II), metabolic syndrome, and/or other obesity related disorders, is new. Independent claims are also included for: (1) a substance comprising at least one of the activating epitopes of LT-beta -R; (2) a pharmaceutical composition comprising a beta -receptor activating agent or the substance above; (3) use of the substance comprising an activating epitope of LT-beta -R for the preparation of an activating LT-beta -R antibody, or for the preparation of a vaccine for the prevention and/or treatment of obesity, associated diabetes (type II), metabolic syndrome, and/or other obesity associated disorders; and (4) a method for the selection of a LT-beta -R activating agent. ACTIVITY : Anorectic; Antidiabetic; Metabolic. C57BL6/J mice were divided into treatment group and a control group. The treatment group was injected a rat-anti-mouse LT-beta -R IgG2a (treatment group), the control group was injected a corresponding isotype control antibody (rat IgG2a). The mice were fed a normal chow diet, and food and acidified water were given ad libitum, for six weeks. After a 4-hour fast, mice were weighed, and then anaesthetized with FFM (fentanyl citrate, fluanisone, midazolam). Results showed a significant decrease in adipose tissue mass in the treatment compared to the control group. MECHANISM OF ACTION : Lymphotoxin-Beta-Receptor-Agonist.
BACKGROUND: Multi-organ metastases represent a substantial life-threatening risk for breast cancer (BC) patients. Nonetheless, the current dearth of assessment tools for patients with multi-organ metastatic BC adversely impacts their evaluation.
METHODS: We conducted a retrospective analysis of BC patients with multi-organ metastases using data from the SEER database from 2010 to 2019. The patients were randomly allocated into a training cohort and a validation cohort in a 7:3 ratio. Univariate COX regression analysis, the LASSO, and multivariate Cox regression analyses were performed to identify independent prognostic factors in the training set. Based on these factors, a nomogram was constructed to estimate overall survival (OS) probability for BC patients with multi-organ metastases. The performance of the nomogram was evaluated using C-indexes, ROC curves, calibration curves, decision curve analysis (DCA) curves, and the risk classification system for validation.
RESULTS: A total of 3626 BC patients with multi-organ metastases were included in the study, with 2538 patients in the training cohort and 1088 patients in the validation cohort. Age, grade, metastasis location, surgery, chemotherapy, and subtype were identified as significant independent prognostic factors for OS in BC patients with multi-organ metastases. A nomogram for predicting 1-year, 3-year, and 5-year OS was constructed. The evaluation metrics, including C-indexes, ROC curves, calibration curves, and DCA curves, demonstrated the excellent predictive performance of the nomogram. Additionally, the risk grouping system effectively stratified BC patients with multi-organ metastases into distinct prognostic categories.
CONCLUSION: The developed nomogram showed high accuracy in predicting the survival probability of BC patients with multi-organ metastases, providing valuable information for patient counseling and treatment decision making.
FIELD: molecular biology, genetic engineering, biochemistry. SUBSTANCE: gene encoding streptokinase is subjected for amplification using PCR and recombined with procaryotic expressing vector - plasmid PLY-4. Cells of E. coli pSTE-SK-I are transformed to express gene SK by temperature effect. Obtained bacteria are fermented and disrupted by high pressure. Inclusion bodies are collected and the isolated r-sk is purified for two stages involving ionic exchange and gel-filtration. Purity and yield of r-sk are high at low cost. EFFECT: improved method of streptokinase preparing. 8 cl, 2 dwg, 2 tbl, 2 ex
PURPOSE: After glioblastoma (GB) recurrence, prognosis is very cumbersome. Therefore, health-related quality of life (HRQoL) and neurocognitive functioning (NCF) have become important endpoints in clinical trials when evaluating novel treatments. We aimed to evaluate the HRQoL and NCF in patients with recurrent glioblastoma (rGB) treated with a combination of surgical intervention (reoperation or biopsy) and intracerebral immune checkpoint inhibition.
METHODS: Patients who participated in the trial (N = 23), at a single-center university hospital were included. Data were collected using 3 patient-reported outcome measures (EORTC-QLQ-C30, EORTC-QLQ-BN20, and HADS) and computerized NCF testing. In the responder group, baseline values were compared to results at a 6-month follow-up. Additionally, exploratory analyses compared baseline HRQoL and NCF between responders and non-responders.
RESULTS: There were five responders and 18 non-responders. When comparing the mean and individual baseline with follow-up results for the responders, we observed overall a stable to slight clinically relevant improvement of HRQoL in multiple subsets of the questionnaires while maintaining a stable NCF. One patient deteriorated on anxiety and depression symptoms from baseline to follow-up.
CONCLUSIONS: In patients that responded to intracerebral immunotherapy in our institutional trial, HRQoL and NCF remained stable over time, suggesting that no detrimental effect on cognitive function or quality of life may be expected with this treatment approach. Furthermore, there seems to be an overall tendency for responders to score better on HRQoL and NCF than non-responders at baseline.
INTRODUCTION: The text examines the impact of artificial intelligence (AI) in the context of rare diseases, exploring how patients turn to AI resources for health information, especially in situations where doctor-patient communication is limited. The article features the case of a doctor specializing in clinical psychology and psychotherapy, diagnosed with thymoma and Good's syndrome, who uses AI resources during his illness.
METHODS: The capabilities of five chatbots based on Large Language Models (LLMs), such as GPT-3.5, GPT-4, Bing Chat, Google Bard, and Anthropic Claude are explored. The AIs were queried on various aspects of the disease, from pre-diagnosis and diagnosis to therapeutic, psychological, and caregiver management issues. The responses were evaluated by five experts based on criteria such as: accuracy, relevance, coherence, clarity, practical utility, ethical considerations, empathy, and capacity to respond to questions and concerns.
RESULTS: The results indicate consistency in the evaluators' assessments, with generally high scores across all dimensions. Particularly, systems like Bard and GPT-4 received high ratings in terms of information accuracy and the ability to respond to questions and concerns. Bing and Claude were appreciated for their empathy and tone. Overall, the AI systems' responses were considered appropriate, respectful of ethics and privacy, and useful in the clinical context.
DISCUSSION: The article emphasizes the importance of understanding the reliability and precision of responses provided by AI systems in the clinical field. Although these systems offer high-quality responses, there is significant variability in their performance. Healthcare professionals must be aware of these differences and use such tools cautiously. AI can provide support in some aspects of care but cannot replace genuine human empathy and understanding. Integrating AI into clinical practice presents potential but also challenges, particularly the possibility of providing incorrect information.
CONCLUSIONS: The AI systems demonstrate the ability to provide useful advice on clinical and psychological issues, but their use requires caution. It is crucial to distinguish the benefits of AI for patients from the challenges it presents for healthcare professionals. As AI technology continues to evolve, it is essential that its integration into the clinical field is accompanied by continuous research and evaluations, to ensure safe and effective use in the healthcare sector.
Volunteers (aim is 36 completers) will participate in a double-blind study conducted over a period of about 14-17 weeks including sessions for screening, food and beverage diary review (Phase 1), drug exposure and choice sessions (Phase 2), and no-choice exposure sessions (Phase 3). During Phases 2 and 3, participants will orally ingest capsules containing varying doses of commonly prescribed over-the-counter medications and/or placebo. During screening, participants will be asked questions about participants' general characteristics including demographic information, mood, and personality. Participants will also be examined to determine medical eligibility. Eligible participants will proceed to Phase 1 in which participants will be asked to eliminate certain foods and beverages from participants diet, record participants daily food and beverage consumption and attend the laboratory approximately three times per week to discuss participants' food diaries. During Phases 2 and 3 food and beverage restrictions will remain in place and participants will report to the laboratory 2-5 times weekly in order to ingest study capsules and fill out questionnaires (e.g., about participants' current mood). After leaving the laboratory, participants will be asked to fill out surveys remotely in order to describe the effects of that session's capsules on mood and preference.
Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO daily on days 1-21, and dexamethasone PO daily on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
FIELD: pharmacy. SUBSTANCE: method involves administration to mammalian with solid tumors of 1,2,4-benzotriazine oxide defined as compound of the formula (I). This compound enhances cytotoxicity of CHEMOTHERAPEUTIC agent and administrated 0.5-24 h before the latter. Invention relates to sets for treatment of such tumors that involve CHEMOTHERAPEUTIC agent and amount of 1,2,4-benzotriazine oxide of the formula (I) that enhances cytotoxicity of agent. Invention relates to also the use of compound of the formula (I) that is able to enhance cytotoxicity with regard to cancer tumor, for production of medicinal agent for therapeutic administration to mammalian with so tumors 0.5-24 h before treatment onset of indicated tumor with CHEMOTHERAPEUTIC agent. EFFECT: enhanced effectiveness of treatment.
Provided is an A.C.C. extract from a combination of medicinal herbs, which are  Phellodendron  bark,  Scutellaria baicalensis, Paeonia lactiflora  Pall,  Dictamnus dasycarpus  Turcz,  Anemarrhena asphodeloides , Alumen,  Dryobalanops aromatica  Gaertner,  Mentha arvensis  var. piperascens,  Inula helenium, Syringa velutina  var.  kamibayashii, Corydalis incisa, Eclipta prostrata, Lonicera japonica , and  Glycyrrhiza uralensis , and a composition having the same as an active ingredient. The A.C.C. extract of the present invention reduces production of TNF-α IL-1β and IL-6, thereby regulating the expression of iNOS and thus exhibiting an anti-inflammatory effect inhibiting NO production. Also clinically, the A.C.C. extract of the present invention is a substance that alleviates symptoms such as diaper rash and miliaria through anti-inflammatory and antimicrobial activitities and can be used as an effective anti-inflammatory agent.
PURPOSE: A composition for mitochondria functional regulation including necrox-5 is provided to treat arrhythmia, ventricular fibrillation, cardiac failure and ischemic heart damage by secluding mitochondria calcium channel. CONSTITUTION: A composition for mitochondria functional regulation includes necrox-5 as an effective ingredient. The necroX-5 is represented by chemical formula 1. The necroX-5 is 5-(1,1-Dioxo-thiomorpholin-4-ylmethyl)-2-phenyl-1H-indol-7-yl-(tetrahydro-pyran-4-ylmethyl) -amine. The necrox-5 controls the function of mitochondria by secluding a mitochondria calcium channel. The composition treats and prevents arrhythmia, ventricular fibrillation, disease of cardiac failure or ischemic heart damage. The mitochondria calcium channel blocker includes necrox-5 as the active ingredient.
Freezing of gait (FOG) is arguably one of the most debilitating motor symptoms experienced by individuals with Parkinson's disease (PD), and negatively impacts quality of life (Walton et al., 2015). Furthermore, advanced FOG does not respond well to treatments commonly used in Parkinson's disease (Nutt et al., 2011), therefore warranting the use of adjunct treatment options. The development of potential treatment strategies for FOG should focus on the underlying mechanism. The cross-talk model of FOG proposes that FOG may be caused by an overload of cognitive, limbic, and sensorimotor system activity in the basal ganglia, resulting in a depletion of dopaminergic resources, leading to FOG (Lewis \& Barker, 2009). Hence, based on the cross-talk model, treatments targeting the cognitive, sensorimotor and limbic systems independently may lead to a reduction in FOG episodes. Previous studies have demonstrated the efficacy of therapies targeting these domains in PD and healthy individuals, however, these have yet to be explored in FOG. Therefore, the purpose of this study is to evaluate cognitive, sensorimotor, and limbic therapies in individuals with FOG.

This study will employ a within-subjects design, in which participants will undergo all three treatments in a randomized counterbalanced order. Sessions for each type of treatment will occur for 1 hour, twice weekly for a period of 4 weeks. Participants will also undergo pre- and post-test assessments prior to and following each 4-week treatment period. The cognitive training will utilize the "Smartbrain Pro" computer software, which has previously demonstrated efficacy in individuals with Parkinson's disease (Paris et al., 2011). The sensorimotor training group will participate in proprioceptive training of the upper and lower limbs. This training will entail a target matching task, in which participants will produce active and self-defined movements while blindfolded (i.e. without visual feedback). The limbic training group will undergo cognitive behavioural therapy (CBT) focusing solely on anxiety symptoms.
The usual starting dose for hydromorphone hydrochloride tablets is 2 mg to 4 mg, orally, every 4 to 6 hours. Appropriate use of the hydromorphone hydrochloride tablets must be decided by careful evaluation of each clinical situation.

The usual adult dosage of hydromorphone hydrochloride oral solution is one-half (2.5 mL) to two teaspoonfuls (10 mL) (2.5 mg to 10 mg) every 3 to 6 hours as directed by the clinical situation. Oral dosages higher than the usual may be required in some patients.

A gradual increase in dose may be required if analgesia is inadequate, as tolerance develops, or if pain severity increases. The first sign of tolerance is usually a reduced duration of effect.

Patients with hepatic and renal impairment should be started on a lower starting dose (see CLINICAL PHARMACOLOGY: Pharmacokinetics and Metabolism).
OBJECTIVE: The risk of hydrocephalus following hemispherectomy for drug resistant epilepsy (DRE) remains high. Patients with pre-existing hydrocephalus pose a postoperative challenge, as maintaining existing shunt patency is necessary but lacks a clearly defined strategy. This study examines the incidence and predictors of shunt failure in pediatric hemispherectomy patients with pre-existing ventricular shunts.
METHODS: We performed a retrospective chart review at our center to identify pediatric patients diagnosed with DRE who were treated with ventricular shunt prior to their first hemispherectomy surgery. Demographic and perioperative data were obtained including shunt history, hydrocephalus etiology, epilepsy duration, surgical technique, and postoperative outcomes. Univariate analysis was performed using Fisher's exact test and Pearson correlation, with Bonferroni correction to a = 0.00625 and a = 0.01, respectively.
RESULTS: Five of nineteen (26.3%) patients identified with ventriculoperitoneal shunting prior to hemispherectomy experienced postoperative shunt malfunction. All 5 of these patients underwent at least 1 shunt revision prior to hemispherectomy, with a significant association between pre- and post-hemispherectomy shunt revisions. There was no significant association between post-hemispherectomy shunt failure and valve type, intraoperative shunt alteration, postoperative external ventricular drain placement, hemispherectomy revision, lateralization of shunt relative to resection, postoperative complications, or postoperative aseptic meningitis. There was no significant correlation between number of post-hemispherectomy shunt revisions and age at shunt placement, age at hemispherectomy, epilepsy duration, or shunt duration prior to hemispherectomy.
CONCLUSIONS: Earlier shunt revision surgery may portend a subsequent need for shunt revision following hemispherectomy. These findings may guide neurosurgeons in counseling patients with pre-existing ventricular shunts prior to hemispherectomy surgery.
The invention discloses erysipelas eliminating particle prescription and its manufacturing method. Its ingredients are: weeping forsythia 450-550; honeysuckle 600-700, gardenia 300-360, angelica 450-500, job's-tears kernel 450-550; peony root-bark 450-550, tulip 300-360, liquorice 120-200. The weeping forsythia, honeysuckle, angelica and tulip are extracted the volatile oil with water backflow method and packaged with beta-cyclodextrin. The peony root-bark is added with water and heated to reclaim fraction, carries on cold storage and recrystallization, and filter. Above mentioned two dredges are stewed with liquorice, and combines the liquid, the liquid is filtered, the filtered liquid is mixed with above mentioned water solution, and they are condensed into plaster, then carries on alcohol depositing, filters the supernatant, reclaims the alcohol and condense into plaster. The gardenia is stewed with alcohol, reclaims alcohol from the filtered liquid, and then it is condensed into plaster. The job's-tears kernel is crashed into tiny powder, and produced into particle with above mentioned plaster, and adds them into the volatile oil package, and so on.
The use of a remotely controlled mandibular protrusion (RCMP) device allows for customization of treatment by titrating the extent of mandibular protrusion during a polysomnogram. Use of the RCMP device has a high degree of positive and negative predictive value in determining the effectiveness and degree (effective target protrusive position) of mandibular advancement need with oral appliance therapy (Remmers, 2013). Preliminary data from 4 patients (Hoekena 2006) indicates that patients with a significant response to oral appliance therapy (\>50% reduction in AHI) may have a better response to MMA. This study will determine the efficacy of MMA in patients with moderate to severe OSA, and determine if the RCMP titration can predict success or failure with MMA for treatment of OSA.

Patients will undergo detailed history and physical examination by Oral \& Maxillofacial Surgery. Those patients found to be potential candidates for jaw advancement (MMA) surgery will be recruited to enroll in the study. Once consented and enrolled, study participants will undergo a titration study using a remote controlled mandibular positioner (RCMP titration study) to evaluate changes in polysomnographic parameters (i.e. Apnea-hypopnea index and oxygen saturation) with mandibular protrusion. Patients will then undergo maxillomandibular advancement surgery (MMA surgery). During MMA surgery, a standard 10 mm advancement of the upper and lower jaw is performed. Slight modifications may be made to the degree of advancement in order to achieve acceptable facial esthetics. Data from the RCMP titration study will not affect how the MMA surgery is performed. After surgery, participants will have a follow-up polysomnogram four to eight months post-operatively to assess for treatment response and compared this to the predicted response based on the RCMP titration study.